BioWorld

Nov. 14, 2007

Ambit's Series D Raises $50M For Kinase Inhibitor Program

With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today) Read More

Competition For Few Compounds Drives Up Deal Costs, Complexity

Acambis Partners West Nile Vaccine In $80M Sanofi Deal

Smoke Clears; Pfizer Paying Nektar $135M In Exubera Deal

AVAX Starts Pivotal Testing With M-Vax Cancer Vaccine

VaxGen, Raven Get 'Fresh Start' Via Merger To Focus On Cancer

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...

More than two to tango: multispecifics at ESMO TAT

BioWorld Science

Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or...